Kornimate/medical-research-clean huggingface dataset:
dc vaccines targeting hpv16/18 e6/e7 protein to regress cini/cin2

Conditions: Cervical Intraepithelial Neoplasia

Summary: to establish therapeutic dendritic cell (dc) vaccines targeting hpv 16/18 e6/e7 protein to block the progression of cin1/cin2 to cervical cancer and evaluate the safety and efficacy of the vaccines.

cervical cancer is the second most common cause of cancer-related deaths among women worldwide with 10000 new cases each year in china. the high-risk human papillomavirus (hpv) was the major cause of cervical cancer. the oncoproteins e6 and e7 encoded by hpv16 and 18, are consistently expressed in hpv-associated cervical cancer and are responsible for the cervical cancer malignant progression. targeting the e6/e7 proteins could be very helpful to regress the cin 1/2 and block the tumorigenesis. by this research, we aim to establish the hpv16/18 e6/e7 peptide library which could induce the strong anti-virus immune response and to vaccinate the cin 1/2 patients with dendritic cell vaccines loaded hpv 16/18 e6/e7 epitopes. including: 1. to create an effective hpv 16/18 e6/e7 antigen peptide library using netmhcspan software based on the mhc-i subtype of the chinese population and screen e6/e7protein peptides with high binding affinity to mhc molecules; 2. to develop hpv 16/18 e6/e7- pulsed dc vaccines and evaluate the safety and efficacy of dc vaccines; 3. the patients are vaccinated with the hpv16/18 e6/e7- pulsed dc vaccines 4. to evaluate the safety and efficacy of dc vaccines loaded with hpv 16/18 e6/e7.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years ≤ 70 years at the time of informed consent 2. hpv type 16/18 positive 3. pathologically confirmed cin1/2 and no other cervical disease 4. adequate organ functions. exclusion criteria: 1. severe allergy to drugs 2. women of child-bearing potential who are pregnant or breast-feeding 3. any form of primary immunodeficiency 4. with serious cardiac, cerebrovascular and primary diseases 5. with a history of severe mental illness

Keywords: cervical intraepithelial neoplasia human papillomavirus dentritic vaccine e6/e7 protein
randomized study of failed scs trials comparing outcomes using the observational mechanical gateway (omg) connector

Conditions: Chronic Pain

Summary: the purpose of this study is to evaluate patient preference of the boston scientific corporation (bsc) commercially approved spinal cord stimulation (scs) systems with the observational mechanical gateway (omg) in patients who failed non-bsc scs trial therapy.

spinal cord stimulation (scs) is an established therapy for the treatment of chronic pain of the trunk and/or limbs. standard practice includes a screening trial, typically lasting from 3 days to 7 days or more, for both the physician and the patient to evaluate whether scs therapy is appropriate for permanent implantation. screening trial success (hereafter referred to as a trial) is often considered predictive of long-term success of the therapy, although that has never been definitively demonstrated. boston scientific corporation (bsc) developed the observational mechanical gateway (omg) connectors to allow patients who previously underwent an scs trial using medtronic or st jude medical leads, operating room cables (or-cables), and external trial stimulators (etss), to be able to connect to bsc commercially approved spinal cord stimulation (scs) trial systems to evaluate the bsc scs therapy in the physician office setting prior to removal of the non-bsc leads.

Eligibility criteria:
key inclusion criteria: * chronic intractable pain of the trunk and/or lower extremities * history of trunk and/or lower extremity pain lasting at least 6 months * study candidate completed a spinal cord stimulation (scs) trial of a fda-approved non-boston scientific corporation (non-bsc) system, exclusively for the treatment of chronic intractable pain of the trunk and/or lower extremities, that will not proceed to permanent implantation due to unsatisfactory treatment or in the physician's opinion received sub-optimal results * currently implanted with fda-approved non-bsc scs lead(s) exclusively in the thoracolumbar epidural space that are temporarily anchored for non-surgical removal at the termination of the screening trial period and which are approved for use with either the observational mechanical gateway (omg) a or omg-m, per the omg directions for use key exclusion criteria: * primary source of pain is cancer-related, pelvic, visceral or angina * investigator-suspected gross lead migration during the non-bsc trial period which may preclude the study candidate from receiving adequate scs therapy * study candidate reports \<10% paresthesia coverage of overall pain while running the preferred stimulation settings on the non-bsc scs system at the end of the non-bsc scs screening trial period * study candidate unwilling to tolerate implantation with an scs system
apatinib and chemotherapy sequential treatment with cervical cancer

Conditions: Cervical Cancer

Summary: the study is the single arm and single center clinical trials，we conduct the phase ii clinical trial to further explore the efficacy and safety of apatinib and chemotherapy sequential treatment with advanced recurrence of metastatic cervical cancer


Eligibility criteria:
inclusion criteria: * the pathological diagnosis of recurrent or metastatic cervical cancer; * eastern cooperative oncology group (ecog) performance status of 0 - 1; * life expectancy of more than 3months; * with normal marrow, liver and renal function： * blood routine examination ：hb≥90g/l，anc ≥1.5×10\*9/l，plt≥80×10\*9/l； * biochemical examination: total bilirubin (tbil) of ≤1.5 upper normal limitation (unl)，alanine aminotransferase (alt) and aspartate aminotransferase (ast) of ≤2.5 unl or ≤5 unl ，acreatinine (cr) of ≤ 1.25 unl; creatinine clearance rate ≥ 45ml/min (cockcroft-gault); * with written informed consent signed voluntarily by patients themselves . * with good compliance and agree to accept follow-up of disease progression and adverse events. exclusion criteria: * uncontrolled hypertension * suffered from grade ii or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias * with abnormal coagulation function， bleeding tendency or treating with thrombolysis and anticoagulation * history of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, bleeding ulcer, occult blood ≥ (++), and vasculitis) =\< 3 months prior to randomization; * uncured the wound or fracture * centrally located tumors of local invasion of major blood vessels, or researchers think that patients may invade the important blood vessels and cause fatal bleeding (ct or mri); * factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and intestinal obstruction); * urine protein \>++, or urine protein in 24 hours\> 1.0g * accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment * history of uncontrolled psychotropic drug abuse or mental disorders; * prior vegfr inhibitor treatment ; * other malignancy within before or at the same time other than basal cell skin cancer, or carcinoma in situ of the cervix;
refractive error and biometry in retinopathy of prematurity

Conditions: Retinopathy of Prematurity

Summary: the investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.

purpose: to compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (rop) treated with intravitreal injection of ranibizumab (ivr), versus bevacizumab (ivb), at a corrected age of 3 years. methods: a retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either ivr or ivb for type 1 rop, from april 2011 to april 2014. comparison of refractive errors and biometric findings between the two groups was performmed and multivariate analysis of possible factors contributive to visual acuity was also performmed

Eligibility criteria:
inclusion criteria: * children with type 1 retinopathy of prematurity * children received anti-vascular endothelial growth factors (bevacizumab or ranibizumab) exclusion criteria: * children withour retinopathy of prematurity * children with retinopathy of prematurity received laser therapy

Keywords: bevacizumab biometry ranibizumab refractive error retinopathy of prematurity
current situation of health care in women with hbv or hcv infection

Conditions: HBV; HCV

Summary: a multicenter, retrospective study conducted in male and female population infected with hbv or hcv in east china. hcv part, study will enroll 500 hcv antibody positive and hcv rna positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (svr12) among eligible female and male patients. hbv part, study will enroll 2000 hbsag positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.

some of the sociocultural factors may prevent women infected with hbv or hcv benefiting from quality health care. limited articles have ever reported the situation of health care in women with viral hepatitis. a previous study found that low hcv knowledge was observed in females, which was related to a lower willingness to be treated for hcv. besides that, in other disease areas like hypertension, studies found that females have less awareness of their disease but have higher control over it compared with males. these findings might reflect the differences in health literacy levels which might influence disease outcomes, healthcare-seeking and adherence to treatment. this research aims to fill the data gaps of the gender differences in cascade of care in hbv and hcv, to facilitate patient activation, especially for women. so far, data on the current health care status in hbv-infected women is scarce. with the expansion of treatment indications recommended by china chb guidelines, more female patients will have the opportunity to gain timely and necessary treatment. this study will analyze the cascade of care by observing the duration from diagnosis to treatment and treatment adherence for women. and this knowledge will serve as a guide for interventions for the management of viral hepatitis, as well as effectively finding and activating patients who meet treatment criteria but are not being treated.

Eligibility criteria:
inclusion criteria: hbv cohort - * ≥18 years old * serum hbsag positive for \>6 months * treatment naïve or, * patients who had been previously treated for hbv but discontinued for at least 1 year before enrollment hcv cohort - * ≥18 years old * hcv-ab positive * hcv rna positive * treatment naïve or, * patients who had been previously treated for hcv with a regimen containing interferon and not had a sustained virologic response. exclusion criteria: * hbv/hcv co-infection * hiv * history of hepatic decompensation or hepatocellular carcinoma * other carcinoma * other severe liver disease * severe comorbidity like cardiovascular disease, diabetes etc. * patients who had discontinued previous hcv treatment because of an adverse event. * patients who had previously received any nucleotide analogue hcv ns5b inhibitor or any ns5a inhibitor * patients who had discontinued previous hbv treatment because of an adverse event.
clinical study of minimally invasive ponto surgical technique (mips) - design iteration

Conditions: Bone Conduction Deafness; Unilateral Deafness; Middle Ear Deafness; Mixed Hearing Loss

Summary: the objective of the study is to compare the outcomes after a surgical procedure with minimally invasive ponto surgery (mips, test group) and tissue preservation surgery (control) for placing oticon medical ponto implants and abutments.


Eligibility criteria:
inclusion criteria: * 18 years or older. * patient indicated for an ear level bone anchored sound processor. * healthy bone quality to allow for 4mm implant insertion. exclusion criteria: * intraoperative switch to an alternative surgical technique * patients undergoing re-implantation (on the side being included in the study) * previous participation in the c47 study. * inability to participate in follow-up. * psychiatric disease in the medical history. * mental disability. * presumed doubt, for any reason, that the patient will be able to show up on all follow-ups. * diseases or treatments known to compromise the bone quality at the implant site, e.g. radiotherapy, osteoporosis, diabetes mellitus. * patients with natural skin height of \>12mm (as there will be additional skin reduction needed)
genoss des prospective multicenter registry

Conditions: Coronary Artery Disease; Myocardial Ischemia; Myocardial Infarction

Summary: this registry is a clinical post-market evaluation of the genoss des in subjects requiring coronary revascularization with drug eluting stents (des).

percutaneous coronary intervention (pci) is the main stream of treatment of coronary artery disease. drug-eluting stents (des) have dramatically reduced the rates of restenosis and target lesion revascularization (tlr) compared with bare-metal stents (bms). newer-generation des with a durable polymer such as xience (abbott, us) and resolute (medtronic, us) were widely used. however, the concern about late stent thrombosis due to hypersensitivity reaction from the polymer is still existed. recently, des with a biodegradable polymer such as biomatrix (biosensors, switzerland), nobori (terumo, japan), orsiro (biotronik, switzerland), and synergy (boston scientific, us) was rapidly adopted and it is expected to reduce the late stent thrombosis. recently, new biodegradable des with thin struts was developed in south korea. the genoss des (genoss, korea) has an l-605 cobalt chromium (cocr) platform with a strut thickness of about 70 µm and the stent is coated a combination of sirolimus drug with concentration of 1.15µg/mm2 and an abluminal biodegradable pla and plga polymers. this study is conducted to evaluate efficacy and safety of genoss des in the treatment of patients with coronary artery disease.

Eligibility criteria:
inclusion criteria: * subject is ≥ 19 years * subject implanted genoss des within 1 month * subject has signed informed consent for data release * subject is geographically stable and willing to participate at all follow-up assessments exclusion criteria: * subject did not sign informed consent for data release * known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for pci, cobalt chromium, sirolimus or contrast media * pregnancy * subject with life expectancy less than 12 months * subject with cardiogenic shock * planned surgery within 12 months of pci unless dual antiplatelet therapy will be maintained * currently participating in another study and primary endpoint is not reached yet.

Keywords: observational registry all-comers open label registry genoss des multicenter stenting coronary artery disease coronary revascularization percutaneous coronary intervention
tau pet/ct imaging in the mismatch prospective cohort study (mpc-tau)

Conditions: Alzheimer's Disease

Summary: to collect tau pet/ct imaging in older adults diagnosed with mild cognitive impairment (mci) or alzheimer's disease (ad) in the mismatch prospective cohort study (mpc-tau) study to determine relationship to clinical, cognitive, and other biomarker data. findings from this study will likely provide insight into the phenotypic variability of alzheimer's disease and other related pathologies.

this is a cross-sectional study using the radiotracer av-1451 to determine the relationship of tau pathology to other biomarker data of mpc participants. all subjects will already have been enrolled in the mpc study. for the current protocol, participants will provide informed consent before beginning any study procedures. after screening assessments, participants will undergo pet/ct scan imaging with av-1451.

Eligibility criteria:
inclusion criteria: 1. enrolled in mpc study (protocol 850160 at upenn; protocol 2022p002447 at mgh). 2. reliable study partner to accompany participant to the pet/ct scan 3. a brain mri must be performed within 6 months prior to their study av-1451 tau pet/ct scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3t high-resolution imaging of medial temporal lobe structures. exclusion criteria: 1. have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. 2. have evidence of structural abnormalities such as major stroke or mass on mri that is likely to interfere with analysis of the pet/ct scan. 3. inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. 4. have a history of significant ongoing alcohol or substance abuse based on self- report. 5. female participants of child-bearing age will not be able to participate in this study, determined by self-report.
treating anxiety after stroke (task)

Conditions: Anxiety Disorders; Stroke; Transient Ischemic Attack

Summary: the task (treating anxiety after stroke) trial is a feasibility randomized controlled trial. it aims to evaluate the feasibility of i) web-enabled trial procedures, and ii) the task intervention in stroke and tia patients

anxiety after stroke and transient ischaemic attack (tia) is common. it is distressing and potentially debilitating. currently, post-stoke psychological care is inadequate. there is no definitive evidence to guide treatment of anxiety post-stroke. the task intervention is a centralized model for delivering personalised therapy for treating anxiety post-stroke using telephone and web-technology. the task intervention includes: * treatment website and telephone support * learning ways to overcome anxiety after stroke/'mini-stroke' * relaxation techniques * weekly online tasks * therapeutic videos * text reminders and participant record card * useful links to stroke resources and websites the investigators designed the task trial to be web-enabled, so that it can be conducted entirely remotely. in the task feasibility randomized controlled trial, the investigators aim to evaluate the feasibility of: i) web-enabled trial procedures: online recruitment, remote eligibility checking, electronic informed consent, online self-reported outcome surveys ii) feasibility of the task intervention in stroke and tia patients this trial received a favourable opinion from the south east scotland research ethics committee (ref: 17/ss/0143)

Eligibility criteria:
inclusion criteria: 1. aged 18 or above 2. a diagnosis of stroke (ischaemic, primary haemorrhagic) or tia-probable, definite, or ocular 3. at least one month after being discharged to the community from clinic or hospital ward 4. has anxiety symptoms a. at least one anxiety symptom should be present on the 6-item anxiety screening questions derived from gad-7 and modified fear questionnaire(ref). 5. have capacity to give informed consent 6. able to communicate in english on the telephone 7. can access the internet via a computer/ tablet/ smartphone 8. residents within nhs lothian regions (eh postcodes and fk1) exclusion criteria: 9. people already taking part in a clinical trial of treatment intended to improve psychosocial outcomes e.g. emotional distress, anxiety, depression, emotionalism, fatigue, social functioning, quality of life are excluded.

Keywords: stroke transient ischemic attack anxiety psychotherapy
a comparison of rocuronium 0.3 mg/kg, and 0.9 mg/kg for induction of anesthesia in elderly patients.

Conditions: Neuromuscular Blockade; Neuromuscular Blockade, Residual; Anesthesia; Intubation Complication

Summary: the number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia. during anesthesia neuromuscular blocking agents (nmba) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. there is a risk of residual neuromuscular block when using nmbas like rocuronium. the aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years.

the number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia within the next decades. elderly patients are at higher risk of major morbidity and mortality and are characterized by a reduction in cardiac output, liver function and renal function. these physiological changes influence pharmacodynamics and pharmacokinetics of drugs administered during anesthesia. rocuronium is a nondepolarizing neuromuscular blocking drug with an onset time of approximately 70 s and a clinical duration of action of approximately 50 min. according to previous studies. during anesthesia rocuronium is administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. rocuronium is primarily metabolized in the liver (70 % unmetabolized via the bile) and excreted via the kidneys. onset time and duration of action of rocuronium should be assessed by objective neuromuscular monitoring. also, this reduces the risk of residual neuromuscular block which is defined as a train of four (tof) ratio less than 0.9. especially elderly patients have a high incidence of residual neuromuscular block. the collected data regarding the effect of rocuronium in elderly patients may change the treatment so these patients receive the correct dose for optimal intubating conditions. also, detection of duration of action of different doses of rocuronium may reduce the risk of residual block and postoperative respiratory complications the aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years.

Eligibility criteria:
inclusion criteria: * age ≥ 80 * scheduled to elective surgery (expected duration time of surgery \> 1 hour) under general anesthesia with intubation and use of rocuronium. * american society of anesthesiologists (asa) physical status classification i to iii * informed consent (see appendix 1) * read and understand danish exclusion criteria: * neuromuscular disease * known allergy to rocuronium * prone position * indication for rapid sequence induction